We report the largest retrospective, phase IV non-interventional, observational study of ofatumumab therapy in heavily pre-treated patients with poor-prognosis chronic lymphocytic leukemia. Total number of patients was 103; median age was 65 years (range 39-85). Median number of prior lines of therapy was 4 (range 1-13), including, in most cases, rituximab-, fludarabine-and alemtuzumab-based regimens; 13 patients had been allografted. Of 113 adverse events, 28 (29%) were considered to be directly related to ofatumumab. Grade 3-4 toxicities included neutropenia (10%), thrombocytopenia (5%), anemia (3%), pneumonia (17%), and fever (3%). Two heavily pre-treated patients developed progressive multifocal leukoencephalopathy. On an intention-to-treat analysis, the overall response rate was 22% (3 complete response, 1 incomplete complete response). Median progression-free and overall survival times were 5 and 11 months, respectively. This study confirms in a daily-life setting the feasibility and acceptable toxicity of ofatumumab treatment in advanced chronic lymphocytic leukemia. The complete response rate, however, was low. Therefore, treatment with ofatumumab should be moved to earlier phases of the disease. Ideally, this should be done in combination with other agents, as recently approved for ofatumumab plus chlorambucil as front-line treatment for patients unfit for fludarabine. This study is registered at clinicaltrials.gov identifier:01453062. ABSTRACT achieves higher surface density, efficiently activates in vitro complement-dependent cytotoxicity (CDC), and shows improved antibody-dependent cell-mediated phagocytosis (ADCC) even when the CD20 expression is low.
Introduction
Treatment of chronic lymphocytic leukemia (CLL) has dramatically improved. In 2010, the combination of fludarabine, cyclophosphamide and rituximab (FCR), developed by the MD Anderson group, 1 was shown in a randomized trial conducted by the German CLL Study Group to result in a higher response rate, a longer progression-free-survival (PFS), and better overall survival (OS) than fludarabine plus cyclophosphamide in untreated, fit patients. 2 These results were corroborated by observational studies. [3] [4] [5] As a result, chemoimmunotherapy (CIT), particularly FCR, is considered the treatment of choice for CLL. However, only 40%-60% of patients obtain complete remission (CR), and most patients eventually relapse. Furthermore, FCR produces considerable hematologic toxicity, particularly among patients over 70 years of age. This has generated an interest in strategies to improve both the efficacy and tolerability of CIT, including the development of new anti-CD20 monoclonal antibodies.
Ofatumumab (HuMax-CD20; Arzerra [GSK/Genmab]) is a fully human IgG1 2 nd -generation antiCD20 MAb with a molecular weight of 150 KDa. It was produced by immunizing HCo7 and KM mice with a murine cell line transfected with human heavy and light chain genes. Ofatumumab binds to a different epitope on the CD20 molecule than rituximab, which is located on the smaller extracellular loop of CD20 and then releases itself very slowly from the target (reduced off-rates). As compared to rituximab, ofatumumab in vitro
The results of a pivotal study10 led to the approval of ofatumumab in October 2009 by the US Food and Drug Administration (FDA) for the treatment of CLL refractory to both fludarabine and alemtuzumab, and likewise, in April 2010, the European Medicines Agency (EMA) issued a conditional marketing authorization for the same indication although this required further clinical data in a dailylife setting. 11, 12 In this context, the European Research Initiative on CLL (ERIC) conducted a non-interventional, observational phase IV study to determine the safety and efficacy of ofatumumab in patients with pre-treated and poor prognosis CLL in daily practice, outside clinical trials.
Methods

Diagnosis, patients and study design
The diagnosis of CLL was made according to WHO/IWCLL criteria. 13, 14 Data from patients treated with ofatumumab outside phase II or III ofatumumab-based trials were included in the study. The presence of bulky lymphadenopathy, fludarabine-and alemtuzumab-refractoriness was registered as recorded by participating investigators. Severity of adverse events (AEs) was graded according to the NCI Common Terminology Criteria for Adverse Events (v.3.0). One hundred and three patients from 25 centers in Europe were accrued. The median number of patients treated in each center was 3 (range 1-15). Data collection started on 30 September 2011 and was completed on 24 November 2012. Twenty-seven patients had been previously reported. 15 All patients were evaluated on an intention-to-treat basis, independently of the number of cycles of therapy received and whether or not all planned therapy was given. Response to therapy was evaluated according to the IWCLL recommendations, 14 changes occurring in clinical stage 16 and modifications in individual parameters. Computed tomography (CT) scans were not used to assess disease status.
Study end points
The main study end points were safety and effectiveness. Progression-free-survival (PFS) was defined as the time from ofatumumab initiation to disease progression or death due to any cause. Overall survival (OS) was defined as the time from ofatumumab initiation to death due to any cause or to last date of contact. PFS and OS were analyzed according to the Kaplan-Meier method. Multivariate analyses were performed using Cox proportional hazard method. Correlation with clinical parameters and adverse events were summarized using descriptive statistics. P<0.05 was considered statistically significant.
All parameters were registered by participating investigators in an ad hoc electronic form and centrally reviewed for consistency. The study was approved by the ethical committees of participating institutions and was in agreement with the recommendations of the Declaration of Helsinki.
Results
Demographics, prior therapy, and patients' characteristics at ofatumumab treatment
Details of patients' main clinical characteristics at start of ofatumumab treatment are shown in Table 1 . Median age was 65 years (range 39-85) and 69% were males.
Median time from diagnosis to ofatumumab treatment was 92 months (range 8-297). Most patients presented with advanced, symptomatic disease. The best response rate ever achieved before ofatumumab therapy was CR in 24 (23%) patients, incomplete CR in 4 (4%), and partial response (PR) in 55 (53%).
Treatment dose and schedule
In most cases, ofatumumab was given according to the approved prescribing information, i.e. 300 mg ofatumumab for the first infusion and 2000 mg thereafter for 8 consecutive weekly infusions, followed 4-5 weeks later by 4 monthly infusions every four weeks. Ofatumumab premedication was given according to procedures of each participating center. Median number of cycles of ofatumumab administered was 9 (range 1-16). Thirteen patients (13%) received other cytotoxic agents (mainly corticosteroids or chlorambucil) along with ofatumumab, 64% received prophylactic antibiotics, 62% antivirals, 17% granulocyte colony-stimulating factor (G-CSF), and 6% erythropoietin.
Toxicity and adverse events
One hundred and fifty-one adverse events were reported in 68 patients, ranging from 1 to 12 events per patient. Infusion-related events occurred in 19 subjects (28%), and were grade 3-4 in 4 patients. No infusion-related deaths or 
Response to treatment
In 41 patients (40%), treatment could be given as initially planned. In 81 cases, treatment was discontinued because of disease progression (36%), toxicity (6%), patient decision (2%), or other reasons (16%).
On an intention-to-treat analysis, the overall response rate (ORR) was 22%. Three patients (3%) achieved CR, one (1%) incomplete CR, and 19 (18%) PR (Tables 3 and  4 
Progression-free and overall survival
Median follow-up times from diagnosis and from ofatumumab administration were of 104 and 9.4 months, respectively. At the time of closing the study, 67 patients (65%) had died. Main causes of death were disease progression (61%), infection (28%), CLL unrelated (1%), and unknown (9%). Projected PFS and OS at 12 months were 18% (95%CI: 9-29) and 47% (95%CI: 37-57), respectively. Median PFS and OS were of 5 (95%CI: 3-6) and 11 (95%CI: 9-13) months, respectively. Although the study was not powered to detect differences in patients' subgroups, in exploratory multivariate analysis including age, sex, clinical stage, response to therapy, number of prior lines of therapy (≥4; ≥3), fludarabine-and alemtuzumabrefractoriness, the only variables associated with a shorter OS were clinical stage (advanced vs. early) (HR: 1.50; P<0.05), no response to therapy (HR: 1.45; P<0.05) and prior refractoriness to fludarabine (HR: 1.73 (P=0.018). Cytogenetics was not investigated because of the large number of missing data. Patients responding to ofatumumab had a longer OS than those who failed to therapy (median 24 vs. 10 months; P=0.007). At last contact, 29 (41%) patients categorized as not refractory to fludarabine nor alemtuzumab were alive as compared to 3 (16%) and 5 (23%) of those refractory to fludarabine or alemtuzumab.
Discussion
The main objectives of this study were to determine feasibility, safety and also effectiveness of ofatumumab in patients with unfavorable CLL treated outside clinical trials. This was a requirement of the EMA in its provisional approval in 2010 of ofatumumab therapy for fludarabineand alemtuzumab-refractory CLL (EMA/CHMP/195135/2010) based on phase I and II studies. The results presented here need, therefore, to be compared with those obtained in these studies.
In spite of all necessary caveats when comparing different series of patients, the characteristics of patients included in our study were comparable, if not worse, than those in a phase I/II trial reported by Coiffier et al. 17 and in the pivotal phase II trial by Wierda et al. 10, 18 The vast majority of our patients presented with advanced, symptomatic stage, and adverse clinical and biological features. Also, the time between last therapy and ofatumumab administration was very short, indicating progressive disease. As anticipated, patients had been extensively pre-treated, prior therapy mainly consisting of fludarabine and alemtuzumab, and also rituximab-based regimens; moreover, 13 patients had been allografted. Therefore, this series can be considered as representative of patients with very poor prognosis CLL.
Regarding safety, Coiffier et al. 17 investigated the toxicity of ofatumumab in 33 patients with relapsed or refractory CLL. In 27 patients, 246 adverse events were registered, of which only 7% were reported as grade 3 or 4. Altogether 61% of adverse events were considered to be related to treatment, the majority of which were registered on the day of infusion. Infections were observed in 51% of the patients. In turn, in the study reported by Wierda et al. 10, 18 including 206 patients, the most common adverse events were first infusion-related reactions with an incidence of around 40%, decreasing with subsequent infusions; the most common grade 3-4 adverse events were infections (24%), neutropenia (12%), anemia (5%) and thrombocytopenia (4%). Infections were frequent and often severe. In total, 6 of 59 FA-ref and 5 of 79 BF-ref patients died from infection, including one patient with promyelocytic leumekia (PML). As in all retrospective studies, the appraisal of toxicity in our study could have been hampered by under-reporting and differences in clinical interventions and interpretation of events among participating centers. As an example, the assessment of ofatumumabinfusion related events was blurred by the variability in the medications accompanying ofatumumab administration (e.g. corticosteroids, acetaminophen). Nevertheless, some form of infusion reaction was reported in 19 subjects (28%) but this was of grade 3 or 4 in only 4 patients. However, there were no cases of infusion-related deaths or tumor lysis syndrome. Importantly, only 6% of patients had to discontinue treatment because of toxicity directly related to treatment. However, in 30 cases (29%), treatment had to be delayed because of toxicity. From the hematologic standpoint, main toxicities included infusionrelated events, neutropenia, thrombocytopenia. Main non-hematologic toxicities were anemia and infection, dyspnea, fever, fatigue, rash, and cough. Also, 2 heavily pre-treated patients developed PML, a complication known to occur in CLL and well recognized in subjects receiving anti-CD20 monoclonal antibodies. 19 Recently, concern has been raised about the possibility that ofatumumab could trigger hepatitis B virus (HBV) reactivation. In our series, no case of viral reactivation upon treatment was reported in 4 patients known to be anti-HBs positive.
As far as effectiveness is concerned, Coiffier et al. 17 reported an ORR of 44% at 19 weeks after therapy. Among patients previously treated with rituximab (7 of 33), alemtuzumab (6 of 33) and or fludarabine (20 of 33), 7 responded to treatment. Importantly, however, only 9 patients (27%) had sustained responses. 10, 18 In our series, the large proportion of patients previously treated with rituximab (81%) precluded a meaningful analysis of the response based on this variable. Notably, the ORR was inferior to that previously reported in phase I and phase II trials10,16,18 (22% vs. approx. 50%), most likely due to differences in the time points at which response was assessed, the intention-totreat analysis, and patients' characteristics. Importantly, 27 of 101 evaluable patients (27%) entered CR (n=4) or were down-staged as a result of therapy, Of particular interest is that 21 of 64 patients (33%) in Binet stage C before ofatumumab shifted to Binet A or B stage after treatment, mainly due to the recovery of hemoglobin (Hb) levels and platelet counts (data not shown). Although criteria for treatment-refractoriness were not as robust (investigators' assessment) as in phase I-II trials, patients considered refractory to fludarabine and/or alemtuzumab showed poorer treatment results. Concerning PFS, our results were better than those reported by Coiffier et al. 17 (5 months vs. 106 days) and similar to those reported by Wierda et al. (6 months) . 10 Information on median overall survival was only available in the Wierda et al. study (14 months) , this being slightly longer than in our series (11 months).
In conclusion, the present report includes the largest series of patients with poor-prognosis CLL treated with ofatumumab on a routine basis, outside trials. From this study it can be concluded that results regarding feasibility, toxicity, and effectiveness of ofatumumab in daily life are comparable to those obtained in pioneer phase I and phase II trials. 10, 16, 18 Unfortunately, the response rate and outcome in all these studies, including ours, has been poor. This observation has been confirmed in a randomized phase III trial comparing ibrutinib versus ofatumumab (ORR: 4%; median PFS: 8 months in the ofatumumab arm). 20 Ofatumumab, therefore, joins other anti-CD20 monoclonal antibodies such as rituximab and obinutuzumab in the armatorium for CLL treatment. Looking forward to the future, several studies have, not surprisingly, shown much better results in untreated patients and when ofatumumab has been given in combination with other agents, [21] [22] [23] [24] [25] fulfilling the paradigms that combination therapy is better than single agents and that effective treatments should be given before the disease becomes refractory to therapy. It is important, therefore, to extend treatment with ofatumumab, particularly in combination with other agents, to earlier phases of CLL. The recent approval by the FDA and EMA of the combination ofatumumab plus chlorambucil as front-line therapy for patients with CLL unfit for fludarabine 25 is an important step in that direction. In line with this, the availability of signal transduction inhibitors, such as the BTK inhibitor ibrutinib and the PI3κd inhibitor idelasilib, and also BCL2 antagonists (ABT199), will make it possible to study the effectiveness of ofatumumab given not only alongside standard cytotoxic agents but also with new non-cytotoxic compounds.
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